Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity

European Journal of Medicinal Chemistry

Volumn 93, Issue , 2015, Pages 564-573

  Chinthala, Yakaiah ^a   Thakur, Sneha ^a   Tirunagari, Shalini ^a   Chinde, Srinivas ^b   Domatti, Anand Kumar ^b   Arigari, Niranjana Kumar ^a   Srinivas, K V N S ^a   Alam, Sarfaraz ^a   Jonnala, Kotesh Kumar ^a   Khan, Feroz ^a   Tiwari, Ashok ^b   Grover, Paramjit ^b  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

1,2,3 Triazoles; Anticancer activity; Chromanochalcones; Molecular docking; Glucosidase inhibition

Indexed keywords

(E) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL) 3 (4 ((1 (2 METHYL 3 NITROPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL)PROP 2 EN 1 ONE; (E) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL) 3 (4 ((1 (4 METHOXY 3 NITROPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL)PROP 2 EN 1 ONE; (E) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL) 3 (4 ((1 (4 NITROBENZYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL)PROP 2 EN 1 ONE; (E) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL) 3 (4 ((1PENTYL 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL)PROP 2 EN 1 ONE; (E) 1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL) 3 (4 ((1 (2 METHYL 3 NITROPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL)PROP 2 EN 1 ONE; (E) 1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL) 3 (4 ((1 PENTYL 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL)PROP 2 EN 1 ONE; (E) 1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL) 3 (4 ((1OCTYL 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (2 ETHYLPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (2 ETHYLPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (3 BROMO 4 METHYLPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (3 BROMO 4 METHYLPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (4 ACETYLPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (4 ACETYLPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (4 BROMOPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (4 BROMOPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E) 3 (4 ((1 (4 CHLOROPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (5 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; (E)1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL) 3 (4 ((1 (4 METHOXY 3 NITROPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL)PROP 2 EN 1 ONE; (E)3 (4 ((1 (4 CHLOROPHENYL) 1H 1,2,3 TRIAZOL 4 YL)METHOXY)PHENYL) 1 (7 HYDROXY 2,2 DIMETHYLCHROMAN 6 YL)PROP 2 EN 1 ONE; 1,2,3 TRIAZOLE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; UNCLASSIFIED DRUG; ALPHA GLUCOSIDASE; CHALCONE; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; GLYCOSIDASE INHIBITOR; TRIAZOLE DERIVATIVE; TUMOR ANTIGEN;

A549 CELL LINE; ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LUNG CANCER CELL LINE; MCF 7 CELL LINE; MOLECULAR DOCKING; NEUROBLASTOMA CELL LINE; PROSTATE CANCER CELL LINE; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; METABOLISM; PROTEIN CONFORMATION; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ALPHA-GLUCOSIDASES; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONE; CHEMISTRY TECHNIQUES, SYNTHETIC; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 84923917311     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.02.027     Document Type: Article

References (47)

1. J.B. Gibbs, Mechanism-based target identification and drug discovery in cancer research, Science 287 (2000) 1969-1973.
2. H. Varmus, The new era in cancer research, Science 312 (2006) 1162.
3. C.T. Hsieh, T.J. Hsieh, M. El-Shazly, D.W. Chuang, Y.H. Tsai, C.T. Yen, S.F. Wu, Y.C. Wu, F.R. Chang, Synthesis of chalcone derivatives as potential antidiabetic agents, Bioorg. Med. Chem. Let. 22 (2012) 3912-3915.
4. Z.H. Israili, Advances in the treatment of type 2 diabetes mellitus, Am. J. Ther. 18 (2011) 117-152.
5. J.H. Cheng, C.F. Hung, S.C. Yang, J.P. Wang, S.J. Won, C.N. Lin, Synthesis and cytotoxic, anti-inflammatory, and anti-oxidant activities of 20,50-dialkoxylchalcones as cancer chemopreventive agents, Bioorg. Med. Chem. 16 (2008) 7270-7276.
6. S.F. Nielsen, T. Boesen, M. Larsen, K. Schonning, H. Kromann, Antibacterial chalconeseebioisosteric replacement of the 40-hydroxy group, Bioorg. Med. Chem. 12 (2004) 3047-3054.
7. C. Zhan, J. Yang, Protective effects of isoliquiritigenin in transient middle cerebral artery occlusion-induced focal cerebral ischemia in rats, Pharmacol. Res. 53 (2006) 303.
8. M. Liu, P. Wilairat, M.L. Go, Antimalarial alkoxylated and hydroxylated chalcones [corrected]: structure-activity relationship analysis, J. Med. Chem. 44 (2001) 4443-4452.
9. M.L. Go, X. Wu, X. Liu, Chalcones: an update on cytotoxic and chemoprotective properties L, Curr. Med. Chem. 12 (2005) 481-499.
10. (a) O. Sabzevari, G. Galati, M.Y. Moridani, A. Siraki, P. O'Brien, J. Chem. Biol. Interact. 148 (2004) 57
11. (b) Y.S. Lee, S.S. Lim, K.H. Shin, Y.S. Kim, K. Ohuchi, S.H. Jung, Biol. Pharm. Bull. 29 (2006) 1028
12. (c) Z. Rozmer, T. Berki, P. Perjesi, Toxicol. In Vitro 20 (2006) 1354.
13. C.T. Hsieh, T.J. Hsieh, M. El Shazly, D.W. Chuanq, Y.H. Tsai, C.T. Yen, S.F. Wu, Y.C. Wu, F.R. Chang, Synthesis of chalcone derivatives as potential antidiabetic agents, Bioorg. Med. Chem. Lett. 22 (2012) 3912-3915.
14. H.C. Kolb, K.B. Sharpless, The growing impact of click chemistry on drug discovery, Drug Discov. Today 8 (2009) 1128-1137.
15. S.G. Agalave, S.R. Maujan, V.S. Pore, Click chemistry: 1,2,3-triazoles as pharmacophores, Chem. Asian J. 6 (2011) 2696-2718.
16. V.V. Rostovtsev, K.B. Sharpless, A stepwise Huisgen cycloaddition process: copper (I)-catalyzed regioselective "Ligation" of azides and terminal alkynes, Angew. Chem. Int. Ed. 41 (2002) 2596-2599.
17. N.S. Vatmurge, B.G. Hazra, V.S. Pore, F. Shirazi, P.S. Chavan, M.V. Deshpande, Synthesis and antimicrobial activity of b-lactam-bile acid conjugates linked via triazole, Bioorg. Med. Chem. Lett. 18 (2008) 2043-2047.
18. M. Whiting, J. Muldoon, Y.C. Lin, S.M. Silverman, W. Lindstron, A.J. Olson, H.C. Kolb, M.G. Finn, K.B. Sharpless, J.H. Elder, V.V. Fokin, Inhibitors of HIV-1 protease by using in situ click chemistry, Angew. Chem. Int. Ed. 45 (2006) 1435-1439.
19. V.D. Bock, D. Speijer, H. Hiemstra, J.H.V. Maarseveen, 1,2,3-Triazoles as peptide bond isosteres: synthesis and biological evaluation of cyclotetrapeptide mimics, Org. Biomol. Chem. 5 (2007) 971-976.
20. N.G. Aher, V.S. Pore, N.N. Mishra, A. Kumar, P.K. Shukla, A. Sharma, M.K. Bhat, Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues, Bioorg. Med. Chem. Lett. 19 (2009) 759-763.
21. J.A. Demaray, J.E. Thuener, M.N. Dawson, S.J. Sucheck, Synthesis of triazoleoxazolidinones via a one-pot reaction and evaluation of their antimicrobial activity, Bioorg. Med. Chem. Lett. 18 (2008) 4868-4871.
22. X.L. Wang, K. Wan, C.H. Zhou, Synthesis of novel sulfanilamide-derived 1,2,3-triazoles and their evaluation for antibacterial and antifungal activities, Eur. J. Med. Chem. 45 (2010) 4631-4639.
23. D.R. Buckle, D.J. Outred, C.J.M. Rockell, H. Smith, B.A. Spicer, Studies on vtriazoles. 7. Antiallergic 9-oxo-1H,9H-benzopyrano[2,3-d]-v-triazoles, J. Med. Chem. 26 (1983) 251-254.
24. M. Whiting, J.C. Tripp, Y.C. Lin, W. Lindstrom, A.J. Olson, J.H. Elder, K.B. Sharpless, V.V. Fokin, Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization, J. Med. Chem. 4 (2006) 7697-7710.
25. M.J. Giffin, H. Heaslet, A. Brik, Y.C. Lin, G. Cauvi, C.H. Wong, D.E. McRee, J.H. Elder, C.D. Stout, B.E. Torbett, A copper(I)-catalyzed 1,2,3-triazole azidealkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant, J. Med. Chem. 51 (2008) 6263-6270.
26. M.S. Costa, N. Boechat, E.A. Rangel, F.D.C.D. Silva, A.M.T.D. Souza, C.R. Rodrigues, H.C. Castro, I.N. Junior, M.C.S. Lourenc, S.M.S.V. Wardell, V.F. Ferreirab, Synthesis, tuberculosis inhibitory activity, and SAR study of Nsubstituted-phenyl-1,2,3-triazole derivatives, Bioorg. Med. Chem. 14 (2006) 8644-8653.
27. S.R. Patpi, L. Pulipati, P. Yogeeswari, D. Sriram, N. Jain, B. Sridhar, R. Murthy, D.T. Anjana, S.V. Kalivendi, S. Kantevar, Design, Synthesis, and structure activity correlations of novel dibenzo [b,d] furan, dibenzo [b, d] thiophene, and N-methylcarbazole clubbed 1,2,3-triazoles as potent inhibitors of mycobacterium tuberculosis, J. Med. Chem. 55 (2012) 3911-3922.
28. R.D. Simone, M.G. Chini, I. Bruno, R. Riccio, D. Mueller, O. Werz, G. Bifulco, Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1,5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents, J. Med. Chem. 54 (2011) 1565-1575.
29. I.S. Bennet, G. Brooks, N.J.P. Broom, S.H. Calvert, K. Coleman, I. Francois, 6-(substituted methylene) penems, potent broad spectrum inhibitors of bacterial b-Lactamse. V. chiral 1,2,3-triazolyl derivatives, J. Antibiot. 44 (1991) 969-978.
30. M.J. Soltis, H.J. Yeh, K.A. Cole, N. Whittaker, R.P. Wersto, E.C. Kohn, Identification and characterization of human metabolites of CAI [5-amino-1-1(4'-chlorobenzoyl-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide), Drug Metab. Dispos. 24 (1996) 799-806.
31. M.J. Fray, D.J. Bull, C.L. Carr, E.C.L. Gautier, C.E. Mowbray, A. Stobie, Structure activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-dionesas Nmethyl-D-aspartate (glycine site) receptor antagonists. 1. Heterocyclic substituted 5-alkyl derivatives, J. Med. Chem. 24 (2001) 1951-1962.
32. D. Imperio, T. Pirali, U. Galli, F. Pagliai, L. Cafici, P.L. Canonico, G. Sorba, A.A. Genazzani, G.C. Tron, Replacement of the lactone moiety on podophyllotoxins and steganacin analogues with a 1,5-disubstituted 1,2,3-triazole via ruthenium-catalyzed click chemistry, Bioorg. Med. Chem. 15 (2007) 6748-6757.
33. L.S. Kallander, Q. Lu, W. Chen, T. Tomaszek, G. Yang, D. Tew, T.D. Meek, G.A. Hofmann, C.K.S. Pritchard, W.W. Smith, T.F. Ho, P.W. Fisher, M.R. Mattern, R.K. Johnson, M.J. Hansbury, J.D. Winkler, K.W. Ward, D.F. Veber, S.K. Thompson, 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo, J. Med. Chem. 48 (2005) 5644-5647.
34. F. Pagliai, T. Pirali, E.D. Grosso, R.D. Brisco, G.C. Tron, G. Sorba, A.A. Genazzani, Rapid synthesis of triazole-modified resveratrol analogues via click chemistry, J. Med. Chem. 49 (2006) 467-470.
35. L. Cafici, T. Pirali, F. Condorelli, E.D. Grosso, A. Massarotti, G. Sorba, P.L. Canonico, G.C. Tron, A.A. Genazzani, Solution-phase parallel synthesis and biological evaluation of combretatriazoles, J. Comb. Chem. 10 (2008) 732-740.
36. C.B. Yim, I. Dijkgraaf, R. Merkx, C. Versluis, A. Eek, G.E. Mulder, D.T.S. Rijkers, O.C. Boerman, R.M.J. Liskamp, Synthesis of DOTA-conjugated multimeric [Tyr3] octreotide peptides via a combination of Cu(I)-catalyzed "Click" cycloaddition and thio acid/sulfonyl azide "sulfo-click" amidation and their in vivo evaluation, J. Med. Chem. 53 (2010) 3944-3953.
37. J. Yoon, J.S. Ryu, A rapid synthesis of lavendustin-mimetic small molecules by click fragment assembly, Bioorg. Med. Chem. Lett. 20 (2010) 3930-3935.
38. J. Vantikommu, S. Palle, P.S. Reddy, V. Ramanatham, M. Khagga, V.R. Pallapothula, Synthesis and cytotoxicity evaluation of novel 1,4-disubstituted 1,2,3-triazoles via CuI catalysed 1,3-dipolar cycloaddition, Eur. J. Med. Chem. 45 (2010) 5044-5050.
39. X.L. Li, Y.J. Lin, Q.Q. Wang, Y.K. Yuan, H. Zhang, X.H. Qian, The novel anti-tumor agents of 4-triazol-1,8-naphthalimides: synthesis, cytotoxicity, DNA intercalation and photocleavage, Eur. J. Med. Chem. 45 (2011) 1274-1279.
40. A. Kamal, S. Prabhakar, M.J. Ramaiah, P.V. Reddy, C.R. Reddy, A. Mallareddy, N. Shankaraiah, T.L.N. Reddy, S.N.C.V.L. Pushpavalli, M.P. Bhadra, Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers, Eur. J. Med. Chem. 46 (2011) 3820-3831.
41. G. Wang, C. Li, L. He, K. Lei, F. Wang, Y. Pu, Z. Yang, D. Cao, L. Ma, J. Chen, Y. Sang, X. Liang, M. Xiang, A. Peng, Y. Wei, L. Chen, Design, synthesis and biological evaluation of a series of pyranochalcone derivatives containing indole moiety as novel anti-tubulin agents, Bioorg. Med. Chem. 22 (2014) 2060-2079.
42. Ch Yakaiah, D. Anand Kumar, Alam Sarfaraz, S.P. Shailendra, A. Niranjan Kumar, G. Namita, K.V.N.S. Srinivas, J. Kotesh Kumar, Feroz Khan, K. Ashok Tiwari, Grover Paramjit, Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring, Eur. J. Med. Chem. 70 (2013) 308-314.
43. T. Mossman, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983) 55-63.
44. K.S. Babu, A.K. Tiwari, P.V. Srinivas, A.Z. Ali, B.C. Raju, J.M. Rao, Yeast and mammalian a-glucosidase inhibitory constituents from Himalayan rhubarb Rheum emodi Wall. Ex Meisson, Bioorg. Med. Chem. Lett. 14 (2004) 3841-3845.
45. G.J. McDougall, F. Shpiro, P. Dobson, P. Smith, A. Blake, D. Stewart, Different polyphenolic components of soft fruits inhibit a-amylase and a-glucosidase, J. Agric. Food Chem. 53 (2005) 2760-2766.
46. K. Kalani, J. Agarwal, S. Alam, F. Khan, A. Pal, S.K. Srivastava, In silico and in vivo anti-malarial studies of 18b glycyrrhetinic acid from Glycyrrhiza glabra, PLoS One 8 (2013) e74761.
47. S. Alam, F. Khan, QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase IIa, Drug Des. Dev. Ther. 8 (2014) 183-195.